In this episode of Managed Care Cast, we speak with Sachin Jain, MD, MBA, SCAN Group and Health Plan's president and CEO, about how the organization made 10% of senior managers’ annual bonuses dependent on how well the gap in medication adherence among diverse populations was reduced.
Even before the pandemic began in 2020, the number of health care organizations appointing chief health equity officers had started to grow. Is this a role for 1 person only or do initiatives to tackle health care disparities and other issues begin at a higher level? And how can change really be accomplished so there is a measurable effect on health outcomes?
In this episode of Managed Care Cast, we speak with Sachin Jain, MD, MBA, who joined SCAN Group and Health Plan 2 years ago as president and CEO. He discusses an effort, recently described in an article in Harvard Business Review, about how SCAN made 10% of senior managers’ annual bonuses dependent on how well the gap in medication adherence among diverse populations was reduced.
The former CareMore executive shares why executives at the top of organizations need to champion and lead initiatives to reduce health care disparities and do more than “virtue signaling” on health equity issues.
Listen to the interview above or through one of these podcast services:
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More